Differences in the transmigration of different dendritic cells

Experimental Hematology

Volumn 34, Issue 6, 2006, Pages 745-752

  Moldenhauer, Anja ^a   Moore, Malcolm A S ^b   Schmidt, Kerstin ^a   Kiesewetter, Holger ^a   Salama, Abdulgabar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; RANTES; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR;

ARTICLE; CELL MATURATION; CELL MIGRATION; CELL STIMULATION; CELL STRUCTURE; CONTROLLED STUDY; DENDRITIC CELL; FETUS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

CELL COMMUNICATION; CELL DIFFERENTIATION; CELL MOVEMENT; CHEMOKINES; DENDRITIC CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA; LYMPHOCYTES; MONOCYTES; TIME FACTORS; TUMOR CELLS, CULTURED;

BOS TAURUS;

EID: 33646715625     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.02.010     Document Type: Article

References (50)

1. Steinman R.M., Witmer-Pack M., and Inaba K. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 329 (1993) 1-9
2. Tjoa B.A., Simmons S.J., Bowes V.A., et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PMSA peptides. Prostate 36 (1998) 39-44
3. Belyakov I.M., Hammond S.A., Ahlers J.D., Glenn G.M., and Berzofsky J.A. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113 (2004) 998-1007
4. Banchereau J., Briere F., Caux C., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767-811
5. Nair S., McLaughlin C., Weizer A., et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 171 (2003) 6275-6282
6. Morse M.A., Deng Y., Coleman D., et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5 (1999) 1331-1338
7. Fong L., Brockstedt D., Benike C., et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167 (2001) 7150-7156
8. De Vries I.J., Krooshoop D.J., Scharenborg N.M., et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63 (2003) 12-17
9. Ridolfi R., Riccobon A., Galassi R., et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med 2 (2004) 2-27
10. Brossart P., Wirths S., Stuhler G., Reichardt V.L., Kanz L., and Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96 (2000) 3102-3108
11. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
12. Nestle F.O., Alijagic S., Gillet M., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4 (1998) 328-332
13. Trefzer U., Herberth G., Sterry W., and Walden P. The hybrid cell vaccination approach to cancer immunotherapy. Ernst Schering Res Found Workshop 30 (2000) 154-166
14. Robert C., Klein C., Cheng G., et al. Gene therapy to target dendritic cells from blood to lymph nodes. Gene Ther 10 (2003) 1479-1486
15. Trefzer U., Herberth G., Wohlan K., et al. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer 110 (2004) 730-740
16. Sallusto F., Palermo B., Lenig D., et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 29 (1999) 1617-1625
17. Hamada T., Möhle R., Hesselgesser J., et al. Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med 188 (1998) 539-548
18. Moldenhauer A., Nociari M.M., Dias S., Lalezari P., and Moore M.A. Optimized culture conditions for the generation of dendritic cells from peripheral blood monocytes. Vox Sang 84 (2003) 228-236
19. Dieu-Nosjean M.C., Vicari A., Lebeque S., and Caux C. Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J Leukoc Biol 66 (1999) 252-262
20. + bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony stimulating factor, and TNF-α. J Immunol 154 (1995) 5851-5861
21. Hagihara M., Li C., Gansuvd B., et al. Extensive and long-term ex vivo production of dendritic cells from CD34 positive umbilical cord blood or bone marrow cells by novel culture system using mouse stroma. J Immunol Methods 253 (2001) 45-55
22. Moldenhauer A., Nociari M., Lam G., Salama A., Rafii S., and Moore M.A. Tumor necrosis factor α-stimulated endothelium: an inducer of dendritic cell development from hematopoietic progenitors and myeloid leukemic cells. Stem Cells 22 (2004) 144-157
23. Claxton D.F., McMannis J., Champlin R., and Choudhury A. Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress. Crit Rev Immunol 21 (2001) 147-155
24. Moldenhauer A., Frank R.C., Pinilla-Ibarz J., et al. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J Leukoc Biol 76 (2004) 623-633
25. + dendritic cell precursor. Blood 93 (1999) 2244-2252
26. Choudhury A., Toubert A., Sutaria S., Charron D., Champlin R.E., and Claxton D.F. Human leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity. Crit Rev Immunol 18 (1998) 121-131
27. + hematopoietic progenitor cells. Stem Cells 22 (2004) 283-291
28. Pietschmann P., Stockl J., Draxler S., Majdic O., and Knapp W. Functional and phenotypic characteristics of dendritic cells generated in human plasma supplemented medium. Scand J Immunol 51 (2000) 377-383
29. Wang L., and Hiebert S.W. TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3. Oncogene 20 (2001) 3716-3725
30. Maeda T., Towatari M., Kosugi H., and Saito H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96 (2000) 3847-3856
31. Vanbervliet B., Bendriss-Vermare N., Massacrier C., et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med 198 (2003) 823-830
32. Syme R., Bajwa R., Robertson L., Stewart D., and Gluck S. Comparison of CD34 and monocyte-derived dendritic cells from mobilized peripheral blood from cancer patients. Stem Cells 23 (2005) 74-81
33. + dendritic cell precursors in vitro. J Leukoc Biol 64 (1998) 235-244
34. + hematopoietic progenitor cells. Immunobiology 198 (1998) 501-513
35. + peripheral blood progenitor cell and monocyte derived dendritic cells: a comparative analysis. Br J Haematol 99 (1997) 490-499
36. +-derived dendritic cells following exposure to various expansion and maturational stimuli. Clin Immunol 98 (2001) 280-292
37. Mohty M., Jarrossay D., Lafage-Pochitaloff M., et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 98 (2001) 3750-3756
38. + acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 94 (1999) 2048-2055
39. Pospisilova D., Borovickova J., Rozkova D., et al. Methods of dendritic cell preparation for acute lymphoblastic leukemia immunotherapy in children. Med Oncol 22 (2005) 79-88
40. Bleul C.C., Fuhlbrigge R.C., Casasnovas J.M., Aiuti A., and Springer T.A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184 (1996) 1101-1109
41. Sozzani S., Allavena P., D'Amico G., et al. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol 161 (1998) 1083-1086
42. Vicari A.P., Vanbervliet B., Massacrier C., et al. In vivo manipulation of dendritic cell migration and activation to elicit antitumour immunity. Novartis Found Symp 256 (2004) 241-254
43. Dieu M.C., Vanbervliet B., Vicari A., et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188 (1998) 373-386
44. Cignetti A., Vallario A., Roato I., et al. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J Immunol 173 (2004) 2855-2865
45. Bendriss-Vermare N., Chaperot L., Peoc'h M., et al. In situ leukemic plasmacytoid dendritic cells pattern of chemokine receptors expression and in vitro migratory response. Leukemia 18 (2004) 1491-1498
46. Downing J.R. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br J Haematol 106 (1999) 296-308
47. + hematopoietic progenitor cells. Blood 87 (1996) 1292-1302
48. Titzer S., Christensen O., Manzke O., et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 108 (2000) 805-816
49. + progenitor-derived dendritic cell vaccine. Cancer Res 61 (2001) 6451-6458
50. Reichardt V.L., Brossart P., and Kanz L. Dendritic cells in vaccination therapies of human malignant disease. Blood Rev 18 (2004) 235-243